e-Article
Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.
Document Type
Letter
Author
Source
Subject
*ACUTE myeloid leukemia in children
*MYELOID leukemia
*DEOXYADENOSINE
*DAUNOMYCIN
*HEALTH outcome assessment
*DRUG dosage
*PROGNOSIS
*LEUKEMIA treatment
*THERAPEUTICS
*ANTINEOPLASTIC agents
*ADENOSINES
*COMPARATIVE studies
*RESEARCH methodology
*MEDICAL cooperation
*RESEARCH
*EVALUATION research
*RANDOMIZED controlled trials
*ACUTE myeloid leukemia
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0887-6924
Abstract
The article discusses a study which aimed to improve outcome of high-risk (HR) patients by adding moderately dosed 2-chloro-2-deoxyadenosine (2-CDA) to the respective consolidation treatment backbone without increasing the toxicity. The treatment plan included randomization during induction with either liposomal daunorubicin or idarubicin. It suggests that moderate dose 2-CDA does not improve prognosis in HR patients when given during consolidation treatment. [ABSTRACT FROM AUTHOR]